Action figures Phase IIb data on kidney injury drug bodes well for pivotal trials
This article was originally published in Scrip
Executive Summary
Danish biotech firm Action Pharma has reported positive top-line results from a Phase IIb trial of AP214, a drug being developed to prevent post-surgical kidney injury after major thoracic surgery.